文章摘要
马智1,2 宫子木2 官大威1△.间充质干细胞治疗糖尿病的研究进展[J].,2012,12(3):576-578
间充质干细胞治疗糖尿病的研究进展
Development of Mesenchymal Stem Cell inTreating Diabetes
  
DOI:
中文关键词: 间充质干细胞  糖尿病  胰岛素分泌细胞
英文关键词: Mesenchymal stem cell  Diabetes  Insulin-secreting cell
基金项目:
作者单位
马智1,2 宫子木2 官大威1△ 中国医科大学法医学院法医病理学教研室 
摘要点击次数: 1083
全文下载次数: 0
中文摘要:
      糖尿病是目前困扰人类健康的第三大杀手。胰岛移植作为糖尿病的一种有效方法早已得到公认,但是胰岛供体的缺乏和移 植排斥反应的存在限制了胰岛移植的临床应用[1]。胰岛素替代疗法是目前治疗糖尿病最有效的方法。然而这种方法也有许多缺 陷。间充质干细胞(mesenchymal stem cell, MSC)具有多向分化潜能的均质性细胞,具有供源丰富、易于获得、有自由供体、避免免 疫排斥等优点,因而是较为理想的胰岛B 细胞来源[2]。近年来,众多实验研究表明了通过诱导MSC 分化为胰岛B 细胞治疗糖尿 病的可能性。
英文摘要:
      Diabetes is now the third killer that threatens human health in the world. Islets transplantation has been widely accepted as an effective way for diabetes treatment. But transplantation rejection and shortage of cadaver pancreases limit its use in the clinic. Insulin replacement therapy is the widely-used method for diabetes treatment. However, there are many defects for this treatment. Mesenchymal stem cell (MSC) is a kind of cells with multipotent differentiation. It possesses the properties of abundant resources, convenient availability, free donor, and immune privilege etc, indicating that it is the ideal origin for pancreatic islet B type cells. In recent years, more and more studies have shown the possibility of the induction from MSCs into insulin-producing pancreatic islet B type cells.
查看全文   查看/发表评论  下载PDF阅读器
关闭